Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1977 2
1978 3
1979 5
1980 2
1981 5
1982 7
1983 6
1984 3
1985 1
1986 9
1987 9
1988 12
1989 4
1990 10
1991 6
1992 11
1993 8
1994 10
1995 12
1996 11
1997 8
1998 6
1999 10
2000 12
2001 10
2002 15
2003 17
2004 10
2005 9
2006 12
2007 14
2008 14
2009 19
2010 21
2011 26
2012 18
2013 27
2014 22
2015 21
2016 17
2017 22
2018 27
2019 25
2020 19
2021 15
2022 24
2023 13
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

532 results

Results by year

Filters applied: . Clear all
Page 1
Acquired aplastic anemia in children.
Hartung HD, Olson TS, Bessler M. Hartung HD, et al. Pediatr Clin North Am. 2013 Dec;60(6):1311-36. doi: 10.1016/j.pcl.2013.08.011. Epub 2013 Oct 16. Pediatr Clin North Am. 2013. PMID: 24237973 Free PMC article. Review.
How I treat acquired aplastic anemia.
Bacigalupo A. Bacigalupo A. Blood. 2017 Mar 16;129(11):1428-1436. doi: 10.1182/blood-2016-08-693481. Epub 2017 Jan 17. Blood. 2017. PMID: 28096088 Free article. Review.
Acute and chronic graft-versus-host disease remain important complications of BMT. Patient age is a strong predictor of outcome for both IST and BMT, and must be considered when designing therapeutic strategies. ...
Acute and chronic graft-versus-host disease remain important complications of BMT. Patient age is a strong predictor of outcome for b …
Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic.
Zhang Y, He Y, Wang S, Sun J, Jia J, Gong Y, He G, Li J. Zhang Y, et al. Front Immunol. 2023 Jul 11;14:1197982. doi: 10.3389/fimmu.2023.1197982. eCollection 2023. Front Immunol. 2023. PMID: 37497227 Free PMC article.
Little is known about the clinical and laboratory characteristics, and disease prognosis and outcomes in TD-NSAA patients. The clinical and laboratory data of 124 consecutive TD-NSAA patients in the Chinese Eastern Collaboration Group of Anemia from December 2013 and Janua …
Little is known about the clinical and laboratory characteristics, and disease prognosis and outcomes in TD-NSAA patients. The clinic …
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R. Kulasekararaj AG, et al. Blood. 2019 Feb 7;133(6):540-549. doi: 10.1182/blood-2018-09-876805. Epub 2018 Dec 3. Blood. 2019. PMID: 30510079 Free PMC article. Clinical Trial.
Alternative donor transplants for severe aplastic anemia.
Bacigalupo A. Bacigalupo A. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):467-473. doi: 10.1182/asheducation-2018.1.467. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504347 Free PMC article. Review.
When a matched sibling is not available, one can search for a matched unrelated donor or a cord blood unit (CB) in the international registries or, more recently, for an HLA haploidentical (HAPLO) family member. International guidelines call for a course of antithymocyte g …
When a matched sibling is not available, one can search for a matched unrelated donor or a cord blood unit (CB) in the international registr …
Activity of eltrombopag in severe aplastic anemia.
Scheinberg P. Scheinberg P. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):450-456. doi: 10.1182/asheducation-2018.1.450. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504345 Free PMC article. Review.
Supportive care in severe and very severe aplastic anemia.
Höchsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H. Höchsmann B, et al. Bone Marrow Transplant. 2013 Feb;48(2):168-73. doi: 10.1038/bmt.2012.220. Epub 2012 Dec 3. Bone Marrow Transplant. 2013. PMID: 23208312 Review.
Prevention and treatment of complications like hemorrhage, bacterial and fungal infections and of secondary events like alloimmunization to blood products and iron overload have a significant impact on the prognosis of AA patients and need to be carefully observed in daily …
Prevention and treatment of complications like hemorrhage, bacterial and fungal infections and of secondary events like alloimmunization to …
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study.
Fattizzo B, Gurnari C, Cassanello G, Bortolotti M, Awada H, Giammarco S, Consonni D, Sica S, Gandhi S, Trikha R, Large J, Salter S, Maciejewski JP, Barcellini W, Kulasekararaj AG. Fattizzo B, et al. Leukemia. 2023 Dec;37(12):2479-2485. doi: 10.1038/s41375-023-02047-z. Epub 2023 Oct 4. Leukemia. 2023. PMID: 37794100 Free PMC article.
Progression to myeloid neoplasms was limited (8%) and not related to mutational status. Hemolytic PNH developed in 10% of cases, being predicted by detection of small clones at diagnosis. Survival was negatively impacted by age, male gender, LDH, platelets/erythrocyte tran …
Progression to myeloid neoplasms was limited (8%) and not related to mutational status. Hemolytic PNH developed in 10% of cases, being pr …
Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT.
Devillier R, Eikema DJ, Dufour C, Aljurf M, Wu D, Maschan A, Kulagin A, Halkes CJM, Collin M, Snowden J, Renard C, Ganser A, Sykora KW, Gibson BE, Maertens J, Itäla-Remes M, Corti P, Cornelissen J, Bornhäuser M, Araujo MC, Ozdogu H, Risitano A, Socie G, De Latour RP. Devillier R, et al. Haematologica. 2023 Sep 1;108(9):2305-2315. doi: 10.3324/haematol.2022.281876. Haematologica. 2023. PMID: 36951165 Free PMC article.
Late allo-HSCT (i.e., >6 months after SAA diagnosis) was the main poor prognostic factor, specifically increasing the risk of death as the cause of GRFS failure (hazard ratio [HR]=4.08; 95% confidence interval [CI]: 1.41-11.83; P=0.010). ...GRFS was worse in cases of sa …
Late allo-HSCT (i.e., >6 months after SAA diagnosis) was the main poor prognostic factor, specifically increasing the risk of deat …
532 results